filovir
hemorrhag
fever
rare
highli
lethal
diseas
associ
outbreak
develop
caus
agent
ebola
viru
marburg
viru
consid
high
level
biothreat
agent
unit
state
center
diseas
control
prevent
nation
institut
effect
vaccin
use
prophylact
effect
antivir
intervent
manag
diseas
clinic
symptom
marburg
ebola
hemorrhag
fever
difficult
distinguish
drug
effect
either
would
first
one
effect
virus
would
enorm
breakthrough
filovirus
nonseg
negativestrand
rna
virus
produc
filament
envelop
current
four
known
clinic
relev
speci
ebola
singl
speci
marburg
initi
viru
replic
occur
mononuclear
cell
viremia
usual
appar
within
day
death
occur
infect
day
symptom
usual
due
hemorrhag
although
cell
receptor
either
ebola
viru
marburg
viru
fulli
character
broad
cell
tropism
virus
suggest
wide
distribut
receptor
regard
trimer
envelop
glycoprotein
gp
spike
filovirus
believ
mediat
entri
host
cell
via
endocyt
pathway
within
endolysosom
compart
host
endosom
cystein
proteas
cathepsin
cleav
filovir
protein
gener
entri
intermedi
compris
ntermin
fragment
recent
work
indic
cleav
form
ebola
viru
gp
subsequ
interact
niemannpick
endolysosom
cholesterol
transport
trigger
membran
illustr
tabl
pipelin
candid
antifiloviru
therapeut
limit
howev
promis
work
inhibit
viru
entri
host
cell
small
recombin
c
type
immunoadhes
disrupt
viral
rna
directli
target
viral
rna
antisens
oligo
recent
report
tabl
also
indic
oligonucleotidebas
therapeut
appear
farthest
along
develop
reach
phase
clinic
trial
challeng
remain
extent
approach
progress
uncertain
challeng
inher
oligonucleotid
approach
lack
effici
cellspecif
deliveri
although
morpholino
modif
lipid
nanoparticl
formul
use
approach
antifiloviru
applic
specif
target
deliveri
oligonucleotid
diseaserelev
tissu
cell
remain
major
issu
small
molecul
antivir
shown
vivo
efficaci
filovirus
discov
use
cellbas
highthroughput
screen
antivir
mechan
larg
unknown
two
famili
small
molecul
target
host
enzym
sadenosyllhomocystein
hydrolas
endoplasm
reticulum
er
ii
er
especi
interest
broadspectrum
antivir
activ
inhibitor
extens
demonstr
varieti
envelop
virus
mani
famili
tabl
addit
us
fdaapprov
drug
test
new
antivir
effort
result
discoveri
chloroquin
could
disrupt
entri
replic
two
virus
vitro
protect
mice
ebola
viru
challeng
vivo
mani
envelop
morphogenesi
filovirus
appear
depend
upon
er
mediat
process
envelop
glycoprotein
therefor
amplif
propag
filovirus
sensit
imino
sugar
deriv
inhibit
er
due
unusu
antivir
mechan
imino
sugar
complementari
antivir
approach
advantag
broadli
activ
medic
manag
viru
infect
theori
practic
involv
target
either
viru
host
function
target
viru
specifi
function
viral
enzym
dna
rna
polymeras
proteas
helicas
neuraminidas
enorm
effect
offer
opportun
great
hand
drug
target
host
function
upon
virus
reli
approach
skeptic
concern
regard
select
toxic
tabl
show
exampl
attempt
filovirus
discoveri
viru
receptor
may
lead
success
interferon
therapi
make
point
possibl
identifi
host
function
serv
target
broad
spectrum
howev
date
exampl
small
molecul
antivir
target
host
function
retain
broad
activ
short
list
includ
inhibitor
host
cellular
inosin
sadenosyllhomocystein
er
er
inhibitor
thu
rare
group
shown
select
antivir
activ
multipl
envelop
virus
tissu
cultur
sever
case
anim
model
tabl
viral
function
sensit
glucosidas
inhibit
host
function
becom
appreci
touch
briefli
briefli
illustr
figur
nlink
glycan
mammalian
glycoprotein
process
sequenti
remov
termin
glucos
residu
erresid
glucosidas
ii
shortli
becom
glycosyl
specif
asparagin
residu
remark
cell
cultur
toler
complet
shutdown
er
gucosidas
ii
knockout
mice
limit
life
peopl
toler
longterm
month
year
treatment
glucosidas
inhibitor
condit
substanti
repress
er
enzym
howev
troubl
advers
effect
ie
gastric
distress
must
taken
glucosidas
inhibitor
approv
manag
type
ii
diabet
gaucher
diseas
glucosidas
inhibitor
also
advanc
phase
ii
human
trial
manag
hepat
c
viru
human
immunodefici
viru
thu
although
mammalian
cell
anim
toler
signific
even
total
repress
er
glucosidas
mani
virus
inde
complet
life
cycl
mani
envelop
virus
requir
function
exampl
virus
hepadnavirus
flavivirus
filovirus
influenza
viru
significantli
repress
imino
sugar
condit
detect
affect
upon
host
cell
case
anim
experi
limit
affect
upon
host
tabl
sensit
virus
glucosidas
inhibitor
presum
possess
envelop
protein
must
oligomer
appar
requir
glucosidas
process
glycoprotein
presum
enabl
timesensit
proper
calnexin
mediat
fold
taken
togeth
trend
clear
broken
virus
test
far
envelop
virus
bud
intracellular
membran
andor
use
calnexin
depend
pathway
select
sensit
glucosidas
inhibitor
expand
virus
four
famili
caus
hemorrhag
fever
filovirida
bunyavirida
arenavirida
flavivirida
tabl
wide
varieti
structur
divers
compound
natur
synthesi
identifi
glucosidas
success
use
treat
human
exampl
inhibit
intestin
glucosidas
digest
carbohydr
therapeut
manag
type
ii
imino
sugar
nbutyldeoxynorjirimycin
nbdnj
current
approv
treatment
gaucher
diseas
patient
take
near
gram
amount
day
mani
howev
molecular
target
imino
sugar
gaucher
diseas
glucocerebrosid
transferas
highli
sensit
nbdnj
er
nevertheless
success
demonstr
principl
toler
categori
drug
well
practic
therapeut
benefit
benefit
imino
sugar
glucosidas
inhibitor
treatment
viral
infect
less
clear
current
avail
humantest
glucosidas
inhibitor
limit
side
effect
poor
pharmacokinet
properti
make
less
appeal
control
chronic
diseas
exampl
although
glucosidas
inhibitor
cellgosivir
met
viral
reduct
mileston
treatment
chronic
hepat
c
human
studi
drug
advanc
presum
gastriti
frankli
emerg
potent
direct
act
antivir
thu
consist
problem
maintain
serum
concentr
compound
antivir
without
caus
intestin
upset
due
inhibit
intestin
sever
report
show
oral
administr
imino
sugar
deriv
inhibit
dengu
japanes
enceph
viru
mice
well
woodchuck
hepat
viru
although
reduct
viremia
level
limit
result
encourag
note
howev
reduct
viremia
even
log
anticip
significantli
improv
clinic
outcom
reduc
sever
diseas
increas
surviv
along
line
recent
report
imino
sugar
compound
significantli
reduc
mortal
mous
model
lethal
deriv
inhibit
dengu
viru
taken
togeth
result
make
reason
consid
find
broadli
activ
glucosidas
inhibitor
reach
therapeut
level
peopl
multipl
viral
indic
howev
indic
one
major
limit
develop
imino
sugar
antivir
lack
potenc
andor
poor
pharmacokinet
properti
lead
difficulti
maintain
therapeut
drug
concentr
vivo
improv
antivir
potenc
imino
sugar
platform
nbdnj
figur
exampl
base
upon
encourag
vivo
efficaci
result
achiev
dengu
mous
model
synthes
imino
sugar
glucosidas
inhibitor
repres
tert
butyl
urea
u
dnj
submicromolar
antivir
activ
four
famili
hemorrhag
fever
virus
cultur
addit
signific
vivo
efficaci
ebola
marburg
viru
infect
anim
also
achiev
protect
imino
sugar
dnj
head
group
glucos
mimet
competit
inhibitor
nglycan
process
enzym
glucosidas
ii
figur
state
shown
figur
nlink
glycan
follow
transfer
acceptor
asparagin
amino
acid
nascent
glycoprotein
trim
er
seri
sequenti
activ
glycoprocess
enzym
er
ii
first
enzym
function
specif
nascent
nlink
glycoprotein
contain
three
termin
glucos
residu
distal
termini
nglycan
follow
transfer
oligosaccharid
protein
way
enzym
oligosaccharyltransferas
immedi
follow
transfer
termin
glucos
remov
sequenti
action
er
resid
enzym
glucosidas
ii
er
chaperon
calnexin
calreticulin
recogn
monoglucosyl
nglycan
fold
nascent
glycoprotein
process
mannosidas
transfer
golgi
modifi
characterist
complex
carbohydr
structur
underglucosyl
polypeptid
fold
transfer
golgi
may
get
second
chanc
follow
reglucosyl
possibl
calnexin
calreticulin
interact
enzym
udpglucos
glycoprotein
glucosyltransferas
howev
ultim
misfold
unfold
polypeptid
sent
proteasom
degrad
thu
glucosidas
inhibitor
prevent
interact
nascent
nglycoprotien
calnexin
calreticulin
caus
misfold
degrad
misfold
unfold
polypeptid
may
sent
proteasom
degrad
known
year
mani
virus
sensit
glucosidas
inhibit
sensit
sindbi
viru
influenza
viru
fowl
plagu
viru
envelop
protein
report
virus
depend
upon
calnexin
calreticulin
would
thu
expect
sensit
glucosidas
inhibit
develop
biogenesi
theori
virus
bud
endoplasm
reticulum
would
sensit
glucosidas
inhibitor
say
virus
bud
er
would
sensit
glucosidas
inhibitor
inde
infect
retrovirus
bud
plasma
membran
appar
greatli
affect
glucosidas
would
offer
refin
biogenesi
theori
light
known
claim
virus
depend
upon
calnexincalreticulin
type
pathway
morphogenesi
sensit
glucosidas
inhibit
predict
part
seem
support
experiment
result
strikingli
exampl
hepat
b
viru
bovin
viral
diarrhea
viru
sensit
glucosidas
inhibit
two
complet
differ
hepat
b
viru
dna
genom
human
pararetroviru
primarili
infect
hepatocyt
bovin
viral
diarrhea
viru
flaviviru
rna
genom
grow
primarili
nonliv
cell
howev
acquir
envelop
bud
endoplasm
know
also
depend
upon
calnexin
matur
specif
viral
tabl
show
also
greatli
inhibit
glucosidas
inhibitor
concentr
appar
affect
cell
viabil
although
imino
sugar
develop
host
glucosidas
inhibitor
disrupt
viral
glycoprotein
fold
consequenti
virion
morphogenesi
compound
addit
biolog
activ
due
either
ontarget
suppress
er
offtarget
interfer
cellular
exampl
ontarget
inhibit
er
glucosidas
result
viral
glycoprotein
degrad
shown
enhanc
major
histocompat
complex
present
epitop
deriv
viral
envelop
glycoprotein
moreov
chang
glycan
structur
associ
viral
glycoprotein
may
also
alter
interact
ctype
lectin
consequenti
inhibit
proinflammatori
cytokin
addit
imino
sugar
may
even
target
activ
repress
viru
mechan
involv
inhibit
er
offtarget
activ
unusu
compound
develop
case
extra
biolog
effect
upon
antigen
present
cytokin
function
could
even
benefici
may
also
provid
interest
research
lead
howev
essenti
activ
recogn
part
decis
either
progress
disqualifi
compound
compound
offtarget
activ
advanc
activ
must
monitor
imino
sugar
past
propos
primarili
use
chronic
infect
human
immunodefici
viru
chronic
viral
howev
may
best
suit
treat
acut
viral
infect
filovir
hemorrhag
fever
involv
week
therapi
oppos
chronic
infect
may
requir
year
use
would
certainli
avoid
complic
sometim
appear
longerterm
use
moreov
new
gener
compound
brought
forward
design
avoid
reduc
intestin
distress
final
use
lifethreaten
infect
hemorrhag
fever
sever
influenza
either
alon
combin
manag
regim
glucosidas
inhibitor
could
provid
power
option
treatment
tool
kit
